|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 306.4 INR | +5.06% |
|
+17.10% | +22.73% |
| Apr. 18 | India's Biocon developing its own version of Wegovy, clinical trial likely next year | RE |
| Apr. 18 | Biocon Signs Licensing and Supply Pact with Biomm to Commercialize Generic Ozempic in Brazil | MT |
Biocon Limited announced that Mr. Indranil Sen resigned from the position of Chief Financial Officer and Key Managerial Personnel of the Company to pursue other career opportunities outside Biocon Group. Last date of working with the Company would be March 15, 2024. He shall be associated with the organization till the close of business hours of March 31, 2024.
Reason is To pursue opportunities outside the organization.
| 1st Jan change | Capi. | |
|---|---|---|
| +22.73% | 4.39B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
BIOCON LIMITED 
